SMC commitment to ensuring patients' voices are heard in HTA underlined by rise in submissions

A rise in the number of medicines that are accompanied by a patient group submission has underlined SMC's commitment to ensuring the voice of patients are heard in the health technology assessment (HTA) process.

In 2018, 93% (61) of the medicines we assessed featured a patient group submission, up from 87% (54) in 2017.

The figures feature in an end of year flash report put together by our Public Involvement team, who support patient groups to take part in SMC's work.

Read the report 

Back to latest updates